MX2020008931A - Purificacion de anticuerpos. - Google Patents

Purificacion de anticuerpos.

Info

Publication number
MX2020008931A
MX2020008931A MX2020008931A MX2020008931A MX2020008931A MX 2020008931 A MX2020008931 A MX 2020008931A MX 2020008931 A MX2020008931 A MX 2020008931A MX 2020008931 A MX2020008931 A MX 2020008931A MX 2020008931 A MX2020008931 A MX 2020008931A
Authority
MX
Mexico
Prior art keywords
antibody purification
antibody
purification
methods
hydroxyapatite
Prior art date
Application number
MX2020008931A
Other languages
English (en)
Inventor
Timothy Iskra
Ashley Margaret Sacramo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020008931A publication Critical patent/MX2020008931A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proveen metodos para la purificación de anticuerpos; los metodos de purificación provistos implican el uso de una resina de hidroxiapatita (HA) para separar un anticuerpo de interes de una o más impurezas; la impureza puede ser un anticuerpo recortado que comprende un péptido escindido unido en el dominio de la región VH.
MX2020008931A 2018-02-27 2019-02-25 Purificacion de anticuerpos. MX2020008931A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862635943P 2018-02-27 2018-02-27
PCT/IB2019/051498 WO2019166932A1 (en) 2018-02-27 2019-02-25 Antibody purification

Publications (1)

Publication Number Publication Date
MX2020008931A true MX2020008931A (es) 2020-10-01

Family

ID=66049355

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008931A MX2020008931A (es) 2018-02-27 2019-02-25 Purificacion de anticuerpos.

Country Status (12)

Country Link
US (2) US20210017254A1 (es)
EP (1) EP3759134A1 (es)
JP (2) JP7449041B2 (es)
KR (2) KR20240067985A (es)
CN (1) CN111788222A (es)
AU (2) AU2019228377B2 (es)
BR (1) BR112020015603A2 (es)
CA (1) CA3034795A1 (es)
IL (1) IL276816A (es)
MX (1) MX2020008931A (es)
SG (1) SG11202007222RA (es)
WO (1) WO2019166932A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4205938A1 (de) * 1992-02-27 1993-09-02 Medac Klinische Spezialpraep Immunotoxine
EP2336172B1 (en) * 2003-10-27 2014-12-10 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP3036253B1 (en) * 2013-08-19 2020-09-23 F. Hoffmann-La Roche AG Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
KR20170116050A (ko) * 2015-01-16 2017-10-18 앨더 바이오파마슈티컬즈, 인코포레이티드 항-당단백질 항체 및 그의 용도
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2016308383A1 (en) * 2015-08-20 2018-03-15 Genentech, Inc. Purification of FKPA and uses thereof for producing recombinant polypeptides
CN111247167A (zh) 2017-06-02 2020-06-05 辉瑞公司 Flt3的特异性抗体及其用途

Also Published As

Publication number Publication date
TW201936644A (zh) 2019-09-16
IL276816A (en) 2020-10-29
CA3034795A1 (en) 2019-08-27
WO2019166932A1 (en) 2019-09-06
KR20200115569A (ko) 2020-10-07
AU2019228377A1 (en) 2020-08-20
SG11202007222RA (en) 2020-09-29
AU2023203205A1 (en) 2023-06-15
BR112020015603A2 (pt) 2021-01-05
JP7449041B2 (ja) 2024-03-13
JP2019147793A (ja) 2019-09-05
EP3759134A1 (en) 2021-01-06
CN111788222A (zh) 2020-10-16
KR102665277B1 (ko) 2024-05-13
AU2019228377B2 (en) 2023-02-23
JP2024042088A (ja) 2024-03-27
KR20240067985A (ko) 2024-05-17
RU2020128326A3 (es) 2022-03-28
US20240158473A1 (en) 2024-05-16
RU2020128326A (ru) 2022-03-28
US20210017254A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CR20180154A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CR20150088A (es) Anticuerpos anti-notch1 nrr
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
UY37635A (es) Anticuerpos anti phf-tau y sus usos
ECSP19005417A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
CL2019003143A1 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso.
CL2017001461A1 (es) Composiciones y métodos para anticuerpos que se marcan bmp6
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
AR114789A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CR20160392A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de esta
ECSP088675A (es) Métodos y composiciones para actuar sobre relt
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso